Company Filing History:
Years Active: 2025
Title: Laura Ann McAllister: Innovator in Targeted Protein Degradation
Introduction
Laura Ann McAllister is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of biochemistry, particularly in the area of targeted protein degradation. With a total of 2 patents to her name, her work focuses on developing chemical entities that can modulate various biological processes.
Latest Patents
One of her latest patents involves targeted protein degradation related to NIMA Related Kinase 7 (NEK7). This patent describes chemical entities that degrade or inhibit NEK7, which is crucial for treating disorders associated with NLRP3 inflammasome activation. These disorders include autoinflammatory and autoimmune diseases, neurodegenerative conditions, cardiovascular and metabolic disorders, fibrotic disorders, hematological issues, and eye disorders. The chemical entities are believed to directly target NEK7, thereby altering the inflammatory response.
Another significant patent by McAllister focuses on the targeted degradation of Proto-oncogene VAV 1 protein (VAV1). This innovation is aimed at treating inflammatory and autoimmune disorders, showcasing her commitment to addressing complex health challenges through innovative solutions.
Career Highlights
Laura has worked with notable companies such as Monte Rosa Therapeutics AG and Pfizer Corporation. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Throughout her career, Laura has collaborated with esteemed colleagues, including Andreas Ritzen and Vladimiras Oleinikovas. These partnerships have further enhanced her research and development efforts.
Conclusion
Laura Ann McAllister is a trailblazer in the field of targeted protein degradation, with her innovative patents addressing critical health issues. Her work exemplifies the impact of scientific research on improving human health and well-being.